EUVIMEDEUVIMED entdecken
Crossref

Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis

Yuko Kanbayashi, Takeshi Ishikawa, Eigo Otsuji, Koichi Takayama

Oncology · 2024

DOI: 10.1159/000536187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Yuko Kanbayashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Ramucirumab, Bevacizumab, Receptors, Vascular Endothelial Growth Factor, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The risk of thromboembolic events developing limits the dose of antiangiogenic agents, thereby reducing their efficacy. This retrospective study therefore sought to identify predictors for the development of antiangiogenic agent-induced thromboembolic events and to elucidate whether differences in the likelihood of thromboembolic events exist between different antiangiogenic agents or cancer types, to guide future strategies for optimizing safety, efficacy, and quality of life in patients receiving chemotherapy.

Methods

This study retrospectively investigated 468 cancer patients who received chemotherapy with bevacizumab, ramucirumab, or aflibercept at our outpatient chemotherapy center between December 2016 and April 2022. Variables related to the development of thromboembolic events were extracted from the medical records, and multivariate logistic regression analysis was performed to identify predictors for the development of thromboembolic events. The Wilcoxon/Kruskal-Wallis test was used to detect significant differences between groups.

Results

Significant factors included serum albumin level (odds ratio [OR] = 0.363, 95% confidence interval [CI] = 0.193–0.685; p = 0.0017) and diabetes mellitus (OR = 5.356, 95% CI = 1.711–16.769; p = 0.0039). Renin-angiotensin system inhibitors (OR = 0.307) had low OR, although it was not significant. No difference in the development of thromboembolic events was evident between cancer types (p = 0.0781), but differences were identified between the three antiangiogenic agents (p = 0.0132). Ramucirumab was associated with a lower likelihood of thromboembolic events.

Conclusion

Serum albumin level and diabetes mellitus were identified as significant predictors for the development of antiangiogenic agent-induced thromboembolic events. In addition, the likelihood of thromboembolic events did not differ between cancer types but differed between antiangiogenic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RamucirumabBevacizumabReceptors, Vascular Endothelial Growth FactorNeoplasmsThromboembolismAntibodies, Monoclonal, HumanizedAngiogenesis InhibitorsRecombinant Fusion ProteinsHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultAged, 80 and overRisk Factors

Stichwörter der Autor:innen

AfliberceptBevacizumabDiabetes mellitusRamucirumabSerum albumin levelThromboembolic event

Substanzen

RamucirumabBevacizumabafliberceptReceptors, Vascular Endothelial Growth FactorAntibodies, Monoclonal, HumanizedAngiogenesis InhibitorsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Division of Digestive Surgery, Department of Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Zitieren

APA

Kanbayashi, Y., Ishikawa, T., Otsuji, E., & Takayama, K. (2024). Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis. Oncology. https://doi.org/10.1159/000536187

Vancouver

Kanbayashi Y, Ishikawa T, Otsuji E, Takayama K. Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis. Oncology. 2024. doi:10.1159/000536187

BibTeX
@article{Kanbayashi2024,
  author = {Kanbayashi, Yuko and Ishikawa, Takeshi and Otsuji, Eigo and Takayama, Koichi},
  title = {Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000536187}
}
Kostenlos starten →